{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:03:10Z","timestamp":1776880990698,"version":"3.51.2"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Adrenal insufficiency is conventionally treated with daily multiple-dose hydrocortisone, and once-daily low-dose prednisolone is an alternative for glucocorticoid replacement. Clinical trials comparing once-daily low-dose prednisolone with thrice-daily hydrocortisone are lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the differences in metabolism and bone turnover in patients receiving hydrocortisone vs prednisolone for adrenal insufficiency.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This double-blind, crossover randomized clinical trial of multiple-daily standard-dose hydrocortisone vs once-daily low-dose prednisolone (2-5 mg), performed from September 3, 2019, to December 14, 2023, involved adults with adrenal insufficiency. Anthropometrics, biochemical data for cardiometabolic and bone health, and subjective health survey data were collected at days 1, 30, and 120 of each study period for both medications.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Individuals were randomized to receive 4 months of once-daily prednisolone in the morning (with placebos at noon and afternoon) or hydrocortisone at the same times. All participants were crossed over to the alternative treatment for an additional 4 months.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The primary outcome was assessment of bone turnover, detected by change in carboxylated and undercarboxylated osteocalcin between days 1 and 120 in each treatment period. Secondary outcomes included change in weight, body mass index, waist circumference, glycated hemoglobin, and subjective heath survey responses.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Forty-seven participants were randomized, with 46 participants included in the analysis (median [IQR] age, 55.0 [46.5-62.8] years; 24 [52.2%] male). Twenty-four received prednisolone first and 22 received hydrocortisone first. Bone turnover was significantly slowed with prednisolone compared with hydrocortisone as evidenced by a significantly lower level of multiple bone markers, including carboxylated osteocalcin (mean treatment difference, \u22121.22 ng\/mL; 95% CI, \u22122.35 to \u22120.10 ng\/mL;\n P<\/jats:italic>\n \u2009=\u2009.04), undercarboxylated osteocalcin (mean treatment difference, \u22121.38 ng\/mL; 95% CI, \u22122.32 to \u22120.44 ng\/mL;\n P<\/jats:italic>\n \u2009=\u2009.005) (to convert osteocalcin to micrograms per liter, multiply by 1), urinary N-terminal telopeptide (mean treatment difference, \u22129.34 nmol\/mmol; 95% CI, \u221215.4 to \u22123.29 nmol\/mmol;\n P<\/jats:italic>\n \u2009=\u2009.002), and procollagen type 1 N-terminal propeptide (mean treatment difference, \u221213.8 ng\/mL; 95% CI, \u221222.2 to \u22125.49 ng\/mL;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). The mean treatment group difference in weight reduction from baseline was \u22121.87 kg (95% CI, \u22123.02 to \u22120.72 kg;\n P<\/jats:italic>\n \u2009=\u2009.002) for prednisolone treatment compared with hydrocortisone, and this was associated with concordant significantly greater reductions in body mass index (BMI; calculated as weight in kilograms divided by the square of height in meters; treatment difference, \u22120.522; 95% CI, \u22121.01 to \u22120.04;\n P<\/jats:italic>\n \u2009=\u2009.04), waist circumference (treatment difference, \u22122.26 cm; 95% CI, \u22123.97 to \u22120.56 cm;\n P<\/jats:italic>\n \u2009=\u2009.01), and HbA\n 1c<\/jats:sub>\n (treatment difference, \u22120.12% [\u22121.23 mmol\/mol; 95% CI, \u22121.95 to \u22120.51 mmol\/mol];\n P<\/jats:italic>\n \u2009=\u2009.001). There were no differences in safety measures or subjective health outcomes, including all 36-Item Short-Form Health Survey domains and Addison\u2019s Disease-Specific Quality of Life Questionnaire.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, once-daily low-dose prednisolone was associated with slower bone turnover and improvements in cardiometabolic health markers compared with multiple-dose hydrocortisone without compromising well-being. Studies assessing longer-term mortality and morbidity outcomes are needed.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03936517<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.2982","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:00:27Z","timestamp":1774364427000},"page":"e262982","source":"Crossref","is-referenced-by-count":0,"title":["Prednisolone Once Daily vs Hydrocortisone Thrice Daily in Hypoadrenalism"],"prefix":"10.1001","volume":"9","author":[{"given":"Sirazum","family":"Choudhury","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK"},{"name":"Department of Clinical Biochemistry, North West London Pathology, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita","family":"Narula","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Go","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzie","family":"Cro","sequence":"additional","affiliation":[{"name":"Imperial Clinical Trials Unit, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thilipan","family":"Thaventhiran","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Khoo","sequence":"additional","affiliation":[{"name":"Endocrinology, Division of Medicine, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tricia","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK"},{"name":"Department of Clinical Biochemistry, North West London Pathology, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Meeran","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"10274","key":"zoi260124r1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(21)00136-7","article-title":"Adrenal insufficiency.","volume":"397","author":"Husebye","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"zoi260124r2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ejendo\/lvae107","article-title":"Conventional steroids vs. dual-release hydrocortisone on metabolic, cardiovascular, and bone outcomes in adrenal insufficiency: a 10-year study.","volume":"191","author":"Guarnotta","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"zoi260124r3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003088-197904020-00004","article-title":"Clinical pharmacokinetics of prednisone and prednisolone.","volume":"4","author":"Pickup","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"zoi260124r4","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0097","article-title":"Optimising prednisolone or prednisone replacement in adrenal insufficiency.","author":"Sharma","year":"2023","journal-title":"Endocr Connect"},{"issue":"2","key":"zoi260124r5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline.","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"zoi260124r7","doi-asserted-by":"publisher","first-page":"e2759","DOI":"10.1210\/clinem\/dgab096","article-title":"Increased mortality risk in patients with primary and secondary adrenal insufficiency.","volume":"106","author":"Ngaosuwan","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"zoi260124r8","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1210\/clinem\/dgab063","article-title":"Cardiovascular disease in patients with primary and secondary adrenal insufficiency and the role of comorbidities.","volume":"106","author":"Ngaosuwan","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"zoi260124r9","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1210\/clinem\/dgab347","article-title":"Mortality risk in patients with adrenal insufficiency using prednisolone or hydrocortisone: a retrospective cohort study.","volume":"106","author":"Ngaosuwan","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"zoi260124r10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fendo.2017.00070","article-title":"Stress-related and circadian secretion and target tissue actions of glucocorticoids: jmpact on health.","volume":"8","author":"Nicolaides","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"zoi260124r11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025612","article-title":"Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man.","volume":"6","author":"Charmandari","year":"2011","journal-title":"PLoS One"},{"key":"zoi260124r12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.897211","article-title":"Daily glucocorticoid replacement dose in adrenal insufficiency, a mini review.","volume":"13","author":"Caetano","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"zoi260124r13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrendo.2018.5","article-title":"Adrenal disease: imitating the cortisol profile improves the immune system.","volume":"14","author":"M\u00fcller","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"zoi260124r14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1210\/er.2015-1080","article-title":"The functional and clinical significance of the 24-hour rhythm of circulating glucocorticoids.","volume":"38","author":"Oster","year":"2017","journal-title":"Endocr Rev"},{"issue":"6","key":"zoi260124r15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1530\/EJE-08-0880","article-title":"Glucocorticoid replacement therapy and pharmacogenetics in Addison\u2019s disease: effects on bone.","volume":"160","author":"L\u00f8v\u00e5s","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"zoi260124r16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1530\/EJE-08-0578","article-title":"Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens.","volume":"159","author":"Bleicken","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"zoi260124r17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1590\/S0004-27302004000500017","article-title":"One-year clinical evaluation of single morning dose prednisolone therapy for 21-hydroxylase deficiency.","volume":"48","author":"Caldato","year":"2004","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"2","key":"zoi260124r18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1373\/jalm.2016.020206","article-title":"Prednisolone replacement therapy mimics the circadian rhythm more closely than other glucocorticoids.","volume":"1","author":"Williams","year":"2016","journal-title":"J Appl Lab Med"},{"issue":"1","key":"zoi260124r19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40360-025-00865-8","article-title":"Food effects and pharmacokinetic evaluation of oral single-dose prednisone acetate and prednisolone in healthy Chinese subjects.","volume":"26","author":"Cai","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"zoi260124r21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12020-017-1513-0","article-title":"Longitudinal AddiQoL scores may identify higher risk for adrenal crises in Addison\u2019s disease.","volume":"60","author":"Meyer","year":"2018","journal-title":"Endocrine"},{"issue":"8","key":"zoi260124r22","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1210\/jc.2018-00346","article-title":"Circadian rhythm of glucocorticoid administration entrains clock genes in immune cells: a DREAM trial ancillary study.","volume":"103","author":"Venneri","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"zoi260124r23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1210\/jc.2011-1926","article-title":"Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.","volume":"97","author":"Johannsson","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"zoi260124r24","doi-asserted-by":"publisher","first-page":"R66","DOI":"10.1530\/EC-20-0473","article-title":"The use of prednisolone versus dual-release hydrocortisone in the treatment of hypoadrenalism.","volume":"10","author":"Choudhury","year":"2021","journal-title":"Endocr Connect"},{"issue":"3","key":"zoi260124r25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","article-title":"Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial.","volume":"6","author":"Isidori","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"zoi260124r26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1530\/EC-19-0176","article-title":"Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency.","volume":"8","author":"Guarnotta","year":"2019","journal-title":"Endocr Connect"},{"key":"zoi260124r27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.641247","article-title":"Early metabolic benefits of switching hydrocortisone to modified release hydrocortisone in adult adrenal insufficiency.","volume":"12","author":"Bannon","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"zoi260124r28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/cen.13999","article-title":"Improving glucocorticoid replacement profiles in adrenal insufficiency.","volume":"91","author":"Choudhury","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"zoi260124r29","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1210\/js.2019-00046","article-title":"Modified-release hydrocortisone: is it time to change clinical practice?","volume":"3","author":"Stewart","year":"2019","journal-title":"J Endocr Soc"},{"issue":"2","key":"zoi260124r30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1210\/jcem-54-2-332","article-title":"Binding of steroids to mineralocorticoid receptors: implications for in vivo occupancy by glucocorticoids.","volume":"54","author":"Lan","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"zoi260124r31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/mmr.2018.9627","article-title":"Osteocalcin-GPRC6A: an update of its clinical and biological multi-organic interactions [review].","volume":"19","author":"Diaz-Franco","year":"2019","journal-title":"Mol Med Rep"},{"issue":"1","key":"zoi260124r32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/clinchem\/45.1.47","article-title":"Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology.","volume":"45","author":"Brandt","year":"1999","journal-title":"Clin Chem"},{"key":"zoi260124r33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1479-5876-11-201","article-title":"The clinical utility of bone marker measurements in osteoporosis.","volume":"11","author":"Wheater","year":"2013","journal-title":"J Transl Med"},{"issue":"1","key":"zoi260124r34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12020-019-02082-w","article-title":"Prednisolone or hydrocortisone replacement in patients with corticotrope deficiency fasting during Ramadan result in similar risks of complications and quality of life: a randomized double-blind controlled trial.","volume":"67","author":"Chihaoui","year":"2020","journal-title":"Endocrine"},{"key":"zoi260124r6","unstructured":"National Institute for Health and Care Excellence. NICE guideline [NG243]. Adrenal Insufficiency: Identification and Management. Updated 2024. Accessed October 11, 2024. https:\/\/www.nice.org.uk\/guidance\/ng243\/chapter\/Recommendations"},{"key":"#cr-split#-zoi260124r20.1","unstructured":"World Health Organization. Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation, Geneva, 8-11 December 2008. World Health Organization"},{"key":"#cr-split#-zoi260124r20.2","unstructured":"2011:39. Accessed February 17, 2026. https:\/\/www.who.int\/publications-detail-redirect\/9789241501491#.YZp8ihYp28g.mendeley"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2846925\/choudhury_2026_oi_260124_1776877126.03773.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:30:13Z","timestamp":1776879013000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2846925"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.2982","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}